Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT05256225
Title Testing the Addition of Trastuzumab or Trastuzumab/Pertuzumab to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma
Recruitment Recruiting
Gender female
Phase Phase II
Variant Requirements No
Sponsors National Cancer Institute (NCI)
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.